Last updated: 11 July 2024 at 5:30pm EST

John Henneman Net Worth

The estimated Net Worth of John B Iii Henneman is at least $6.58 Milion dollars as of 13 March 2024. Mr. Henneman owns over 6,860 units of Aprea Therapeutics stock worth over $26,208 and over the last 22 years he sold APRE stock worth over $6,355,301. In addition, he makes $201,489 as Lead Independent Director at Aprea Therapeutics.

Mr. Henneman APRE stock SEC Form 4 insiders trading

John has made over 58 trades of the Aprea Therapeutics stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 6,860 units of APRE stock worth $50,009 on 13 March 2024.

The largest trade he's ever made was exercising 100,000 units of Aprea Therapeutics stock on 2 November 2010 worth over $3,025,000. On average, John trades about 5,894 units every 57 days since 2003. As of 13 March 2024 he still owns at least 8,139 units of Aprea Therapeutics stock.

You can see the complete history of Mr. Henneman stock trades at the bottom of the page.

John Henneman biography

John Bell Henneman III serves as Lead Independent Director of the Company. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation, a biotechnology company. From October 2014 to July 2018, Mr. Henneman served as Executive Vice President and Chief Financial Officer at NewLink Genetics Corporation, a biopharmaceutical company. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corp (“Integra”)., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman currently serves on the boards of directors of R1 RCM, Inc., a publicly-held revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.

What is the salary of John Henneman?

As the Lead Independent Director of Aprea Therapeutics, the total compensation of John Henneman at Aprea Therapeutics is $201,489. There are 6 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.

How old is John Henneman?

John Henneman is 58, he's been the Lead Independent Director of Aprea Therapeutics since 2020. There are 9 older and 8 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.

Insiders trading at Aprea Therapeutics

Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... oraz John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.

What does Aprea Therapeutics do?

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Complete history of Mr. Henneman stock trades at Anika Therapeutics, Integra Lifesciences Corp, Orthofix Medical Inc, R1 RCM, SeaSpine Corp oraz Aprea Therapeutics

Osoba	Trans. Transakcja	Łączna cena
John B Iii Henneman Dyrektor	Kupować	$50,009 13 Mar 2024
John B Iii Henneman Dyrektor	Kupować	$75,000 7 Oct 2019
John B Iii Henneman Dyrektor	Opcja Ćwiczenie	$130,500 8 Aug 2023
John B Iii Henneman Dyrektor	Opcja Ćwiczenie	$111,571 21 May 2022
John B Iii Henneman Dyrektor	Kupować	$85,720 18 May 2021
John B Iii Henneman Dyrektor	Sprzedaż	$150,000 5 Aug 2020
John B Iii Henneman Dyrektor	Sprzedaż	$146,800 27 Aug 2018
John B Iii Henneman Dyrektor	Opcja Ćwiczenie	$216,431 13 Jun 2018
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$1,002,400 25 Aug 2014
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$490,000 10 Mar 2014
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$230,350 27 Feb 2014
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$1,262,400 19 Aug 2013
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$118,200 10 Aug 2012
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$186,000 26 Apr 2012
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$199,419 3 May 2011
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$493,800 8 Mar 2011
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$252,677 7 Dec 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$3,025,000 2 Nov 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$290,400 16 Apr 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$575,424 15 Mar 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$312,576 8 Mar 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$646,400 15 Jan 2010
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$105,780 15 Dec 2009
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$719,500 16 Nov 2009
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$191,565 26 Aug 2009
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$455,600 3 Apr 2009
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$372,600 16 Dec 2008
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$371,849 14 Nov 2008
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$70,786 11 Nov 2008
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$148,700 13 Jun 2008
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$1,009,280 5 Dec 2007
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$1,014,600 1 Jun 2007
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$1,014,600 14 May 2007
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$998,409 12 Mar 2007
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$25,335 23 Feb 2007
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Sprzedaż	$1,525,910 15 Nov 2006
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,292 15 Mar 2006
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$32,800 6 Jan 2006
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$108,292 15 Dec 2005
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$36,121 28 Nov 2005
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$55,000 1 Jun 2005
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$2,188 14 Mar 2005
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$16,118 1 Feb 2005
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$67,124 9 Aug 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 12 Jul 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 14 Jun 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 10 May 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 12 Apr 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 8 Mar 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 9 Feb 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,995 19 Jan 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$26,280 12 Jan 2004
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,520 8 Dec 2003
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,520 10 Nov 2003
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,520 13 Oct 2003
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,520 8 Sep 2003
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$17,520 11 Aug 2003
John B Iii Henneman Exec. V.P., CAO oraz Sekretariat	Opcja Ćwiczenie	$23,306 31 Jul 2003

Aprea Therapeutics executives and stock owners

Aprea Therapeutics executives and other stock owners filed with the SEC include:

Christian Schade,
Chairman of the Board, President, Chief Executive Officer
Scott Coiante,
Chief Financial Officer, Senior Vice President, Secretary
Eyal Attar,
Senior Vice President, Chief Medical Officer
Christian S. Schade,
Pres, CEO & Chairman
Dr. Eyal C. Attar M.D.,
Sr. VP & Chief Medical Officer
Scott M. Coiante,
Sr. VP, Company Sec. & CFO
John Henneman,
Lead Independent Director
Bernd Seizinger,
Independent Director
Guido Magni,
Independent Director
Johan Christenson,
Independent Director
Dr. Oren Gilad Ph.D.,
Co-Founder, Pres & Director
Richard Peters,
Director
Fouad Namouni,
Director
Michael Kelly,
Director
Gregory Wessels,
Chief Commercial Officer
Gregory Korbel,
Vice President - Business Development
Lars Abrahmsen,
Senior Vice President, Chief Scientific Officer
Andrea Epstein,
Controller
Dr. Michel Afargan Ph.D.,
Head of Pharmacology Devel.
Hank Breslin,
Head of Medicinal Chemistry
Dr. Rifat Pamukcu M.D.,
Chief Medical Advisor & Director
Dr. Dansu Li Ph.D.,
Head of Technology
Dr. Lars B. Abrahmsen,
Sr. VP & Chief Scientific Officer
Dr. Gregory A. Korbel Ph.D.,
Sr. VP & Chief Bus. Officer
Ventures Iv, L.P.5 Am Co In...,
Marc Duey,
Director
Michael Grissinger,
Director
Rifat Pamukcu,
Director
Ventures Iv, L.P.5 Am Co In...,
V Luxco S.A R.L.Versant Ven...,
Oren Gilad,
President, CEO
Investments Ab Karolinska D...,
Scott M Rocklage,
Director
V Luxco S.A R.L.Versant Ven...,
Vantage I, L.P.Versant Vant...,
Group, Llc Green Jeremy Red...,
Vii, L.P.Health Cap Vii Gp ...,
Jonathan Hepple,
John P. Hamill,
SrVP/CFO/Prin Fin & Acct Ofcr
Gabriela Gruia,
Director
Jean Pierre Bizzari,
Director
Nadeem Q. Mirza,
Chief Medical Officer